Neogen Q1 Revenue Beats, Raises FY27 Guidance on Strong Core Growth
NEOG has more than doubled off its 52-week low of $5.37 on elevated volume (1.9× avg).
Summary
Neogen reported Q1 FY2027 revenue of $222.8M, up 6.5% year-over-year, with core revenue growth of 8.1%. Adjusted EBITDA rose to $41.6M from $35.5M, and adjusted EPS doubled to $0.08 from $0.04. The company raised full-year guidance to $885-890M revenue and $181-183M adjusted EBITDA, up from $880-885M and $180-182M. Net loss of $11.9M reflects the absence of last year's $76.4M divestiture gain, but operating loss narrowed sharply to $1.8M from $16.1M. This follows the FDA warning letter on Hycoat in late September, making the raised guidance and margin expansion a notable positive signal. The Petrifilm manufacturing transition remains on track for November 2026, and the Genomics sale to Zoetis is expected to close by end of December 2026. Neogen also announced a strategic collaboration and equity investment in Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Neogen announced a strategic collaboration and equity investment in Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection.
At the time of this announcement, NEOG was trading at $11.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.37 to $14.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.